Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043324 · ClinicalTrials.gov registry record · Phase 4
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
A Phase 4 study, sponsored by Nguyen Thi Trieu, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
NCT05043324 is a Phase 4 study that has completed, run by Nguyen Thi Trieu, MD. The registered enrollment target is 82 participants.
The verdict
NCT05043324, a Phase 4 study, has completed, sponsored by Nguyen Thi Trieu, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
Study Summary
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.
Interventions
- DRUG AntiCov-220
- DRUG AntiCov-220 (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-02-20 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05043324
The ClinicalTrials.gov registry entry for NCT05043324 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nguyen Thi Trieu, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AntiCov-220 is the first listed.
NCT05043324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05043324 about?
NCT05043324 is a clinical study titled "Prevention and Treatment of Patient Before, During, and After Covid-19 Infection". AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin...
What is the current status of trial NCT05043324?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2020-02-20. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT05043324?
The interventions under investigation include: AntiCov-220 (DRUG), AntiCov-220 (placebo) (DRUG).
Who is sponsoring clinical trial NCT05043324?
This trial is sponsored by Nguyen Thi Trieu, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.